Skip to main content

Saccharomyces boulardii alleviates DSS-induced intestinal barrier dysfunction and inflammation in humanized mice.

  • 2022
  • Food & Function 13(1)
    • Bei Li
    • Haibo Zhang
    • Linlin Shi
    • Rong Li
    • Yanan Luo
    • Yun Deng
    • Shihan Li
    • Ruizhen Li
    • Zhi Liu


Recent clinical studies have demonstrated a beneficial effect of Saccharomyces boulardii (S. boulardii) in inflammatory bowel disease (IBD). However, the underlying mechanisms remain poorly defined. In this study, we investigated the modulating effect of S. boulardii on the intestinal microbiota in humanized mice with dextran sulfate sodium (DSS)-induced colitis. The mice were fed an S. boulardii-supplement diet for 16 days before DSS treatment. The results showed that feeding S. boulardii significantly ameliorated the colon damage and regulated inflammatory responses by modulating the cytokine profile. These changes were found to be associated with an altered microbiome composition and short-chain fatty acid (SCFA) metabolism. Further analysis demonstrated that S. boulardii-derived polysaccharides and polypeptides promoted the growth of certain probiotics and increased the microbial metabolite SCFAs levels. Overall, these findings demonstrated the role of S. boulardii as a potential gut microbiota modulator to prevent and treat IBD.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Saccharomyces boulardiiAltered Gut Microbiome CompositionBeneficial
Saccharomyces boulardiiImproved Colonic HealthBeneficial
Saccharomyces boulardiiIncreased SCFA LevelsBeneficial
Saccharomyces boulardiiRegulated Inflammatory ResponsesBeneficial
⬆ Back to top
Supplement Research and Comparison Website: evidence-based information about supplements, their benefits, potential risks, and their efficacy.
Receive updates about our products, services, sales, and special offers. Unsubscribe anytime. See our Privacy Policy for details on how we handle your information.

Join Our Community

Use to get in touch.